Opinion|Videos|January 27, 2025
Doublet Therapy With Venetoclax-Ibrutinib: Data and Guidelines
Panelists discuss the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on the addition of doublet venetoclax-ibrutinib as a treatment option in ESMO guideline updates and highlight the underlying rationale and data supporting this approach.
Advertisement
Related to this article
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Advertisement
Advertisement
Trending on OncLive
1
Adjuvant Giredestrant Preserves QOL With Sustained Tolerability in ER+, HER2– Early Breast Cancer
2
Arcotatug Tavatecan Improves Survival in CLDN18.2+ Advanced Gastric or GEJ Adenocarcinoma
3
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer
4
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves ctDNA Clearance in Cisplatin-Eligible MIBC
5